Washington, D.C. — National Institutes of Health (NIH) researcher Dr. Nicholas Di Prospero has reported that his team has reached the midpoint of its phase II clinical trial of Idebenone at the National Institute of Neurological Disorders and Stroke (NINDS).
Dr. Di Prospero’s team has examined and tested each of the 48 Friedreich’s ataxia patients enrolled in the phase II clinical trial of Idebenone at NINDS which is part of NIH. The same patients will begin returning for their second and final visits (six months after their first). The second visits will conclude in August and the phase II trial will be over. Dr. Di Prospero’s team will then analyze and publish the results of the study.
Dr. Di Prospero and the NINDS team indicated they want to thank all of the families that expressed interest in the trial, those that sought enrollment and those that have participated. On behalf of all Friedreich's ataxia families everywhere, FARA would like to add its own gratitude to Dr. Di Prospero, the fine NINDS team and to the participating families for making this important clinical trial possible and for keeping it on schedule and on track.
President, Friedreich’s Ataxia Research Alliance